ScripActuate Therapeutics, Inc. grossed $22.4m from its initial public offering of 2.8 million shares priced at $8 each in the 15th biopharmaceutical company IPO in the US in 2024. It was not the smallest
ScripCullinan Oncology, Inc. is changing course and increasing its focus on inflammation and immunology. The company will rebrand as Cullinan Therapeutics, Inc. as it moves CLN-978, its CD19xCD3-directed
ScripEli Lilly ’s subsidiary Prevail Therapeutics has walked away from its collaboration with Precision BioSciences in in vivo Duchenne muscular dystrophy gene-editing. The split has further dented the
ScripMustang Bio Inc. is following an increasing portion of the CAR-T cell therapy field in expanding development of its lead product candidate, MB-106, to include autoimmune diseases in addition to the B